Skip to main content
Trials
Sponsors
Conditions
Drugs
Pricing
Trials
Sponsors
Conditions
Drugs
Pricing
Loading search results
Clinical Trials for "Kezar"
7
trials
Share
Relevance
ID
Status
Phase
Title
Sponsor
NCT03393013
Completed
Phase 1/2
A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis
Kezar Life Sciences, Inc.
ClinicalTrials.gov
NCT03393013
Completed
Phase 1/2
A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis
Kezar Life Sciences, Inc.
NCT04033926
Completed
Phase 2
A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
Kezar Life Sciences, Inc.
ClinicalTrials.gov
NCT04033926
Completed
Phase 2
A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Acti...
Kezar Life Sciences, Inc.
NCT04039477
Withdrawn
Phase 2
A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP
Kezar Life Sciences, Inc.
ClinicalTrials.gov
NCT04039477
Withdrawn
Phase 2
A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With...
Kezar Life Sciences, Inc.
NCT04628936
Completed
Phase 2
Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
Kezar Life Sciences, Inc.
ClinicalTrials.gov
NCT04628936
Completed
Phase 2
Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-61...
Kezar Life Sciences, Inc.
NCT05047536
Terminated
Phase 1
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
ClinicalTrials.gov
NCT05047536
Terminated
Phase 1
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
NCT05569759
Completed
Phase 2
A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
Kezar Life Sciences, Inc.
ClinicalTrials.gov
NCT05569759
Completed
Phase 2
A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA...
Kezar Life Sciences, Inc.
NCT05781750
Terminated
Phase 2
A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)
Kezar Life Sciences, Inc.
ClinicalTrials.gov · CTIS (EMA)
NCT05781750
Terminated
Phase 2
A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZ...
Kezar Life Sciences, Inc.
Result Breakdown
Status
Completed
4 (57%)
Terminated
2 (29%)
Withdrawn
1 (14%)
Phase
Phase 2
5 (71%)
Phase 1/2
1 (14%)
Phase 1
1 (14%)
Top Conditions
Lupus Nephritis
2 (29%)
Dermatomyositis
2 (29%)
Polymyositis
2 (29%)
Show 6 more
Top Sponsors
Kezar Life Sciences, Inc.
7 (100%)
Start your search
Search over 500,000 clinical trials worldwide
Search
Expert
Popular:
Cancer
Diabetes
Alzheimer
COVID-19
Heart Disease